Is China a threat, or an investment opportunity? Post-Hoc Live with Curie.Bio CEO Zach Weinberg

Biopharma companies are increasingly turning to China to find new molecules, and looking to Chinese companies for licensing deals. Some investors are leaning in — but others, like Curie.Bio CEO Zach Weinberg, think they should stay away.This week, Weinberg joins Post-Hoc Live to help us to take stock of the landscape. Be sure to check out our coverage before you tune in: https://endpoints.news/us-investors-divided-on-chinas-biotech-rise/